Abstract:OBJECTIVE:It is well established that regional cerebral metabolic rates for glucose assessed by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with Alzheimer's disease in the mental resting state (eyes and ears covered) provide a sensitive, in vivo metabolic index of Alzheimer's disease dementia. Few studies, however, have evaluated longitudinal declines in regional cerebral glucose metabolism in patients with dementia caused by Alzheimer's disease. In addition, the available studies have not used recently developed brain mapping algorithms to characterize the progression of Alzheimer's disease throughout the brain, and none considered the statistical power of regional cerebral glucose metabolism in testing the ability of treatments to attenuate the progression of dementia.METHOD:The authors used FDG PET and a brain mapping algorithm to investigate cross-sectional reductions in regional cerebral glucose metabolism, longitudinal decline in regional cerebral glucose metabolism after a 1-year follow-up, and the power of this method to evaluate treatments for Alzheimer's disease in patients with mild to moderate dementia. PET scans were initially acquired in 14 patients with Alzheimer's disease and 34 healthy comparison subjects of similar age and sex. Repeat scans were obtained in the patients 1 year later. Power analyses for voxels showing maximal decline over the 1-year period in regional cerebral glucose metabolism (mg/100 g per minute) were computed to estimate the sample sizes needed to detect a significant treatment response in a 1-year, double-blind, placebo-controlled treatment study.RESULTS:The patients with Alzheimer's disease had significantly lower glucose metabolism than healthy comparison subjects in parietal, temporal, occipital, frontal, and posterior cingulate cortices. One year later, the patients with Alzheimer's disease had significant declines in glucose metabolism in parietal, temporal, frontal, and posterior cingulate cortices. Using maximal glucose metabolism reductions in the left frontal cortex, we estimated that as few as 36 patients per group would be needed to detect a 33% treatment response with one-tailed significance of p</=0.005 and 80% power in a 1-year, double-blind, placebo-controlled treatment study.CONCLUSIONS:These findings indicate that brain metabolism as assessed by FDG PET during mental rest is a sensitive marker of disease progression in Alzheimer's disease over a 1-year period. These findings also support the feasibility of using FDG PET as an outcome measure to test the ability of treatments to attenuate the progression of Alzheimer's disease.

Data-driven analysis of regional brain metabolism in behavioral frontotemporal dementia and late-onset primary psychiatric diseases with frontal lobe syndrome: A PET/MRI study

Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD

Metabolic positron-emission tomography/magnetic resonance imaging in primary progressive aphasia and frontotemporal lobar degeneration subtypes: Reassessment of expected [18F]-fluorodeoxyglucose uptake patterns

Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease

Multimodal nonlinear correlates of behavioural symptoms in frontotemporal dementia

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies

Decreased Bilateral FDG-PET Uptake and Inter-Hemispheric Connectivity in Multi-Domain Amnestic Mild Cognitive Impairment Patients: A Preliminary Study

Analysis of Positron Emission Tomography Hypometabolic Patterns and Neuropsychiatric Symptoms in Patients with Dementia Syndromes

Regional cerebral blood flow in behavioral variant of FTD: hypoperfusion patterns and clinical associations

A~(18)F-fluorodeoxyglucose (FDG)/PET Study of Advanced Parkinson's Disease

IC‐P1‐036: Categorical and Correlational Analyses of Baseline Fluorodeoxyglucose Positron Emission Tomography Images from the Alzheimer's Disease Neuroimaging Initiative

Relationship between neuroimaging and cognition in frontotemporal dementia: An FDG‐PET and structural MRI study

Multi-Center Study on Alzheimer'S Disease Using Fdg Pet: Group and Individual Analyses

Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head Comparison

Evaluation of Metabolic Changes in Parkinson's Disease Patients with Different Severities of Cognitive Impairments by 18F-FDG PET/CT Brain Imaging

A ~(18)F-FDG Uptake Study of Brain and Abnormal Brain Connection in Advanced Parkinson's Disease

Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson'S Disease

The Study on Metabolic Brain Networks of Glucose in Patients with early Parkinson's Disease by 18F-FDG PET Imaging

Random forest analysis of midbrain hypometabolism using [18F]-FDG PET identifies Parkinson's disease at the subject-level

Correlation analysis between 18F-fluorodeoxyglucose positron emission tomography and cognitive function in first diagnosed Parkinson's disease patients

Multimodal investigation of neuropathology and neurometabolites in mild cognitive impairment and late-life depression with 11C-PiB beta-amyloid PET and 7T magnetic resonance spectroscopy